1 |
PANENI F, BECKMAN J A, CREAGER M A, et al. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part i[J]. European heart journal, 2013, 34: 2436-2443.
|
2 |
BROWNLEE M. The pathobiology of diabetic complications: A unifying mechanism[J]. Diabetes, 2005, 54: 1615-1625.
|
3 |
RAMASAMY R, GOLDBERG I J. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model[J]. Circulation research, 2010, 106: 1449-1458.
|
4 |
ZHANG W, LIU J, TIAN L, et al. Trib3 mediates glucose-induced insulin resistance via a mechanism that requires the hexosamine biosynthetic pathway[J]. Diabetes, 2013, 62: 4192-4200.
|
5 |
SUGIYAMA S, MIYATA T, HORIE K, et al. Advanced glycation end-products in diabetic nephropathy[J]. Nephrology dialysis transplantation, 1996, 11 Suppl 5: 91-94.
|
6 |
GIACCO F, BROWNLEE M. Oxidative stress and diabetic complications[J]. Circulation research, 2010, 107: 1058-1070.
|
7 |
WADA J, NAKATSUKA A. Mitochondrial dynamics and mitochondrial dysfunction in diabetes[J]. Acta medica okayama, 2016, 70: 151-158.
|
8 |
REN L, HAN F, XUAN L, et al. Clusterin ameliorates endothelial dysfunction in diabetes by suppressing mitochondrial fragmentation[J]. Free radical biology and medicine, 2019, 145: 357-373.
|
9 |
YAMA K, SATO K, ABE N, et al. Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating nrf2 pathway in endothelial cells[J]. Redox biology, 2015, 4: 87-96.
|
10 |
DRYGALSKI K, FERENIEC E, ZALEWSKA A, et al. Phloroglucinol prevents albumin glycation as well as diminishes ros production, glycooxidative damage, nitrosative stress and inflammation in hepatocytes treated with high glucose[J]. Biomedicine and pharmacotherapy=Biomédecine and Pharmacothérapie, 2021, 142: 111958.
|
11 |
BHATTACHARYYA S, FEFERMAN L, TOBACMAN J K. Distinct effects of carrageenan and high-fat consumption on the mechanisms of insulin resistance in nonobese and obese models of type 2 diabetes[J]. Journal diabetes research, 2019: 9582714.
|
12 |
FORBES J M, COOPER M E. Mechanisms of diabetic complications[J]. Physiological reviews, 2013, 93: 137-188.
|
13 |
CADE W T. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting[J]. Physical therapy, 2008, 88: 1322-1335.
|
14 |
DEVASAGAYAM T P, TILAK J C, BOLOOR K K, et al. Free radicals and antioxidants in human health: Current status and future prospects[J]. The journal of the association of physicians of India, 2004, 52: 794-804.
|
15 |
WANG Q, ZHANG M, TORRES G, et al. Metformin suppresses diabetes-accelerated atherosclerosis via the inhibition of drp1-mediated mitochondrial fission[J]. Diabetes, 2017, 66: 193-205.
|
16 |
SORRENTINO V, MENZIES K J, AUWERX J. Repairing mitochondrial dysfunction in disease[J]. Annual review of pharmacology and toxicology, 2018, 58: 353-389.
|
17 |
ZINOVKIN R A, ROMASCHENKO V P, GALKIN I I, et al. Role of mitochondrial reactive oxygen species in age-related inflammatory activation of endothelium[J]. Aging, 2014, 6: 661-674.
|
18 |
CHAN D C. Fusion and fission: Interlinked processes critical for mitochondrial health[J]. Annual review of genetics, 2012, 46: 265-287.
|
19 |
YOULE R J, VAN DER BLIEK A M. Mitochondrial fission, fusion, and stress[J]. Science, 2012, 337: 1062-1065.
|
20 |
ZANDALINAS S I, MITTLER R. Ros-induced ros release in plant and animal cells[J]. Free radical biology and medicine, 2018, 122: 21-27.
|
21 |
ZOROV D B, JUHASZOVA M, SOLLOTT S J. Mitochondrial reactive oxygen species (ros) and ros-induced ros release[J]. Physiological reviews, 2014, 94: 909-950.
|
22 |
VÁSQUEZ-TRINCADO C, GARCÍA-CARVAJAL I, PENNANEN C, et al. Mitochondrial dynamics, mitophagy and cardiovascular disease[J]. The journal of physiology, 2016, 594: 509-525.
|
23 |
KRZYWANSKI D M, MOELLERING D R, WESTBROOK D G, et al. Endothelial cell bioenergetics and mitochondrial DNA damage differ in humans having african or west eurasian maternal ancestry[J]. Circulation cardiovascular genetics, 2016, 9:26-36.
|
24 |
ROSCA M G, HOPPEL C L. Mitochondrial dysfunction in heart failure[J]. Heart failure reviews, 2013, 18: 607-622.
|
25 |
ZONG W X, RABINOWITZ J D, WHITE E. Mitochondria and cancer[J]. Molecular cell, 2016, 61: 667-676.
|
26 |
CADONIC C, SABBIR M G, ALBENSI B C. Mechanisms of mitochondrial dysfunction in alzheimer's disease[J]. Molecular neurobiology, 2016, 53: 6078-6090.
|
27 |
BOSE A, BEAL M F. Mitochondrial dysfunction in Parkinson's disease[J]. Journal of neurochemistry, 2016, 139 Suppl 1: 216-231.
|
28 |
PATIL N K, PARAJULI N, LAMACMILLAN-CROW, et al. Inactivation of renal mitochondrial respiratory complexes and manganese superoxide dismutase during sepsis: Mitochondria-targeted antioxidant mitigates injury[J]. American journal of physiology renal physiology, 2014, 306: F734-743.
|
29 |
SONG Y, COOK N R, ALBERT C M, et al. Effects of vitamins c and e and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: A randomized controlled trial[J]. The American journal of clinical nutrition, 2009, 90: 429-437.
|
30 |
SESSO H D, BURING J E, CHRISTEN W G, et al. Vitamins e and c in the prevention of cardiovascular disease in men: The physicians' health study ii randomized controlled trial[J]. The journal of the American medical association, 2008, 300: 2123-2133.
|